FDA Approves Lyvispah, Granular Form of Baclofen, to Treat Spasticity

FDA Approves Lyvispah, Granular Form of Baclofen, to Treat Spasticity

313794

FDA Approves Lyvispah, Granular Form of Baclofen, to Treat Spasticity

The U.S. Food and Drug Administration (FDA) has approved Lyvispah, a dissolvable granular formulation of baclofen, to treat spasticity in people with multiple sclerosis (MS). The strawberry-flavored formulation, developed by Saol Therapeutics, is particularly suitable to ease flexor spasticity, the involuntary bending of the knees and hips toward the chest, which can be painful and incapacitating. It also may ease spasticity in people with spinal cord injuries or other disorders involving the spinal cord. “We are tremendously excited…

You must be logged in to read/download the full post.